The TIKOSYN clinical program involved approximately 8,600 patients in 130 clinical studies of normal volunteers and patients with supraventricular and ventricular arrhythmias. TIKOSYN was administered to 5,194 patients, including two large, placebo-controlled mortality trials (DIAMOND CHF and DIAMOND MI) in which 1,511 patients received TIKOSYN for up to three years.
In the following section, adverse reaction data for cardiac arrhythmias and non-cardiac adverse reactions are presented separately for patients included in the supraventricular arrhythmia development program and for patients included in the DIAMOND CHF and MI mortality trials (see CLINICAL STUDIES, Safety in Patients with Structural Heart Disease, DIAMOND Studies, for a description of these trials).
In studies of patients with supraventricular arrhythmias, a total of 1,346 and 677 patients were exposed to TIKOSYN and placebo for 551 and 207 patient years, respectively. A total of 8.7% of patients in the dofetilide groups were discontinued from clinical trials due to adverse events compared to 8.0% in the placebo groups. The most frequent reason for discontinuation (>1%) was ventricular tachycardia (2.0% on dofetilide vs. 1.3% on placebo). The most frequent adverse events were headache, chest pain, and dizziness.
Torsade de Pointes is the only arrhythmia that showed a dose-response relationship to TIKOSYN treatment. It did not occur in placebo treated patients. The incidence of Torsade de Pointes in patients with supraventricular arrhythmias was 0.8% (11/1346) (see WARNINGS). The incidence of Torsade de Pointes in patients who were dosed according to the recommended dosing regimen (see DOSAGE AND ADMINISTRATION) was 0.8% (4/525). Table 6 shows the frequency by randomized dose of serious arrhythmias and conduction disturbances reported as adverse events in patients with supraventricular arrhythmias.
| TIKOSYN Dose | Placebo | ||||
|---|---|---|---|---|---|
| Arrhythmia event: | <250 mcg BID N=217 | 250 mcg BID N=388 | >250–500 mcg BID N=703 | >500 mcg BID N=38 | N=677 |
3.7% | 2.6% | 3.4% | 15.8% | 2.7% | |
Ventricular fibrillation | 0 | 0.3% | 0.4% | 2.6% | 0.1% |
Ventricular tachycardia† | 3.7% | 2.6% | 3.3% | 13.2% | 2.5% |
Torsade de Pointes | 0 | 0.3% | 0.9% | 10.5% | 0 |
Various forms of block | |||||
AV block | 0.9% | 1.5% | 0.4% | 0 | 0.3% |
Bundle branch block | 0 | 0.5% | 0.1% | 0 | 0.1% |
Heart block | 0 | 0.5% | 0.1% | 0 | 0.1% |
In the DIAMOND trials, a total of 1,511 patients were exposed to TIKOSYN for 1757 patient years. The incidence of Torsade de Pointes was 3.3% in CHF patients and 0.9% in patients with a recent MI.
Table 7 shows the incidence of serious arrhythmias and conduction disturbances reported as adverse events in the DIAMOND subpopulation that had AF at entry to these trials.
| TIKOSYN | Placebo | |
|---|---|---|
| N=249 | N=257 | |
14.5% | 13.6% | |
Ventricular fibrillation | 4.8% | 3.1% |
Ventricular tachycardia† | 12.4% | 11.3% |
Torsade de Pointes | 1.6% | 0 |
Various forms of block | ||
AV block | 0.8% | 2.7% |
(Left) bundle branch block | 0 | 0.4% |
Heart block | 1.2% | 0.8% |
Table 8 presents other adverse events reported with a frequency of >2% on TIKOSYN and reported numerically more frequently on TIKOSYN than on placebo in the studies of patients with supraventricular arrhythmias.
| TIKOSYN | Placebo | |
|---|---|---|
| Adverse Event | % | % |
|
|
|
headache | 11 | 9 |
chest pain | 10 | 7 |
dizziness | 8 | 6 |
respiratory tract infection | 7 | 5 |
dyspnea | 6 | 5 |
nausea | 5 | 4 |
flu syndrome | 4 | 2 |
insomnia | 4 | 3 |
accidental injury | 3 | 1 |
back pain | 3 | 2 |
procedure (medical/surgical/health service) | 3 | 2 |
diarrhea | 3 | 2 |
rash | 3 | 2 |
abdominal pain | 3 | 2 |
Adverse events reported at a rate >2% but no more frequently on TIKOSYN than on placebo were: angina pectoris, anxiety, arthralgia, asthenia, atrial fibrillation, complications (application, injection, incision, insertion, or device), hypertension, pain, palpitation, peripheral edema, supraventricular tachycardia, sweating, urinary tract infection, ventricular tachycardia.
The following adverse events have been reported with a frequency of ≤2% and numerically more frequently with TIKOSYN than placebo in patients with supraventricular arrhythmias: angioedema, bradycardia, cerebral ischemia, cerebrovascular accident, edema, facial paralysis, flaccid paralysis, heart arrest, increased cough, liver damage, migraine, myocardial infarct, paralysis, paresthesia, sudden death, and syncope.
The incidences of clinically significant laboratory test abnormalities in patients with supraventricular arrhythmias were similar for patients on TIKOSYN and those on placebo. No clinically relevant effects were noted in serum alkaline phosphatase, serum GGT, LDH, AST, ALT, total bilirubin, total protein, blood urea nitrogen, creatinine, serum electrolytes (calcium, chloride, glucose, magnesium, potassium, sodium), or creatine kinase. Similarly, no clinically relevant effects were observed in hematologic parameters.
In the DIAMOND population, adverse events other than those related to the post-infarction and heart failure patient population were generally similar to those seen in the supraventricular arrhythmia groups.
The TIKOSYN clinical program involved approximately 8,600 patients in 130 clinical studies of normal volunteers and patients with supraventricular and ventricular arrhythmias. TIKOSYN was administered to 5,194 patients, including two large, placebo-controlled mortality trials (DIAMOND CHF and DIAMOND MI) in which 1,511 patients received TIKOSYN for up to three years.
In the following section, adverse reaction data for cardiac arrhythmias and non-cardiac adverse reactions are presented separately for patients included in the supraventricular arrhythmia development program and for patients included in the DIAMOND CHF and MI mortality trials (see CLINICAL STUDIES, Safety in Patients with Structural Heart Disease, DIAMOND Studies, for a description of these trials).
In studies of patients with supraventricular arrhythmias, a total of 1,346 and 677 patients were exposed to TIKOSYN and placebo for 551 and 207 patient years, respectively. A total of 8.7% of patients in the dofetilide groups were discontinued from clinical trials due to adverse events compared to 8.0% in the placebo groups. The most frequent reason for discontinuation (>1%) was ventricular tachycardia (2.0% on dofetilide vs. 1.3% on placebo). The most frequent adverse events were headache, chest pain, and dizziness.
Torsade de Pointes is the only arrhythmia that showed a dose-response relationship to TIKOSYN treatment. It did not occur in placebo treated patients. The incidence of Torsade de Pointes in patients with supraventricular arrhythmias was 0.8% (11/1346) (see WARNINGS). The incidence of Torsade de Pointes in patients who were dosed according to the recommended dosing regimen (see DOSAGE AND ADMINISTRATION) was 0.8% (4/525). Table 6 shows the frequency by randomized dose of serious arrhythmias and conduction disturbances reported as adverse events in patients with supraventricular arrhythmias.
| TIKOSYN Dose | Placebo | ||||
|---|---|---|---|---|---|
| Arrhythmia event: | <250 mcg BID N=217 | 250 mcg BID N=388 | >250–500 mcg BID N=703 | >500 mcg BID N=38 | N=677 |
3.7% | 2.6% | 3.4% | 15.8% | 2.7% | |
Ventricular fibrillation | 0 | 0.3% | 0.4% | 2.6% | 0.1% |
Ventricular tachycardia† | 3.7% | 2.6% | 3.3% | 13.2% | 2.5% |
Torsade de Pointes | 0 | 0.3% | 0.9% | 10.5% | 0 |
Various forms of block | |||||
AV block | 0.9% | 1.5% | 0.4% | 0 | 0.3% |
Bundle branch block | 0 | 0.5% | 0.1% | 0 | 0.1% |
Heart block | 0 | 0.5% | 0.1% | 0 | 0.1% |
In the DIAMOND trials, a total of 1,511 patients were exposed to TIKOSYN for 1757 patient years. The incidence of Torsade de Pointes was 3.3% in CHF patients and 0.9% in patients with a recent MI.
Table 7 shows the incidence of serious arrhythmias and conduction disturbances reported as adverse events in the DIAMOND subpopulation that had AF at entry to these trials.
| TIKOSYN | Placebo | |
|---|---|---|
| N=249 | N=257 | |
14.5% | 13.6% | |
Ventricular fibrillation | 4.8% | 3.1% |
Ventricular tachycardia† | 12.4% | 11.3% |
Torsade de Pointes | 1.6% | 0 |
Various forms of block | ||
AV block | 0.8% | 2.7% |
(Left) bundle branch block | 0 | 0.4% |
Heart block | 1.2% | 0.8% |
Table 8 presents other adverse events reported with a frequency of >2% on TIKOSYN and reported numerically more frequently on TIKOSYN than on placebo in the studies of patients with supraventricular arrhythmias.
| TIKOSYN | Placebo | |
|---|---|---|
| Adverse Event | % | % |
|
|
|
headache | 11 | 9 |
chest pain | 10 | 7 |
dizziness | 8 | 6 |
respiratory tract infection | 7 | 5 |
dyspnea | 6 | 5 |
nausea | 5 | 4 |
flu syndrome | 4 | 2 |
insomnia | 4 | 3 |
accidental injury | 3 | 1 |
back pain | 3 | 2 |
procedure (medical/surgical/health service) | 3 | 2 |
diarrhea | 3 | 2 |
rash | 3 | 2 |
abdominal pain | 3 | 2 |
Adverse events reported at a rate >2% but no more frequently on TIKOSYN than on placebo were: angina pectoris, anxiety, arthralgia, asthenia, atrial fibrillation, complications (application, injection, incision, insertion, or device), hypertension, pain, palpitation, peripheral edema, supraventricular tachycardia, sweating, urinary tract infection, ventricular tachycardia.
The following adverse events have been reported with a frequency of ≤2% and numerically more frequently with TIKOSYN than placebo in patients with supraventricular arrhythmias: angioedema, bradycardia, cerebral ischemia, cerebrovascular accident, edema, facial paralysis, flaccid paralysis, heart arrest, increased cough, liver damage, migraine, myocardial infarct, paralysis, paresthesia, sudden death, and syncope.
The incidences of clinically significant laboratory test abnormalities in patients with supraventricular arrhythmias were similar for patients on TIKOSYN and those on placebo. No clinically relevant effects were noted in serum alkaline phosphatase, serum GGT, LDH, AST, ALT, total bilirubin, total protein, blood urea nitrogen, creatinine, serum electrolytes (calcium, chloride, glucose, magnesium, potassium, sodium), or creatine kinase. Similarly, no clinically relevant effects were observed in hematologic parameters.
In the DIAMOND population, adverse events other than those related to the post-infarction and heart failure patient population were generally similar to those seen in the supraventricular arrhythmia groups.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5Pm ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.